For physicians
Treating people with multiple myeloma
Inobrodib has been evaluated in over 450 patients across different tumor types, both as monotherapy and in combination with other standard of care agents. Our current focus is on evaluating the safety and efficacy of inobrodib for the treatment of multiple myeloma.
Participation
If you believe your patient may benefit from treatment with inobrodib but they are not eligible for one of our clinical trials and have exhausted alternatives, pre-approval access may be an option for them.